全球人类尿路致病性大肠埃希菌呋喃妥因耐药率的系统综述与荟萃分析
欧洲流行率最低、亚洲最高;全球流行率从1996-04年的2.8%升至2005-14年的8.2%,近十年(2015-24)降至7.6%。研究间异质性显著且发表偏倚有统计学意义,低收入和中等收入国家流行率更高。
要点
- 全球呋喃妥因耐药UPEC合并流行率为6.9%(95%CI:4.8%-9.7%)。
- 亚洲流行率最高、欧洲最低,低收入和中等收入国家流行率更高。
- 全球流行率从1996-04年2.8%升至2005-14年8.2%,2015-24年为7.6%。
核心结论
- 全球呋喃妥因耐药UPEC分离株存在可观流行率,合并流行率为6.9%(95%CI:4.8%-9.7%)。
- 低收入和中等收入国家的呋喃妥因耐药UPEC流行率更高。
- 应加强抗菌药物管理以减缓全球抗菌药物耐药上升速度。
研究设计与样本
- 遵循PRISMA指南,检索PubMed与Google Scholar,纳入报告人类呋喃妥因耐药UPEC的研究。
- 仅纳入从尿路采集的分离株,按预设标准纳入/排除,采用JBI患病率研究清单评估质量。
- 使用Metafor与Meta(R包)估算合并流行率、评估发表偏倚并进行异质性分析。
主要发现
- 全球呋喃妥因耐药UPEC合并流行率为6.9%(95%CI:4.8%-9.7%)。
- 洲际亚组分析显示欧洲流行率最低、亚洲最高。
- 年代亚组分析显示全球流行率从1996-04年的2.8%升至2005-14年的8.2%,2015-24年为7.6%。
- 研究间存在显著异质性,且发表偏倚有统计学意义。
临床怎么用
- 临床应关注地区与年代差异对呋喃妥因耐药UPEC流行率的影响,结合本地耐药数据评估经验性用药。
- 在低收入和中等收入国家尤其应加强抗菌药物管理以减缓耐药上升。
- 在条件允许处提供充分教育,配合抗菌药物管理措施。
局限性
- 研究间存在显著异质性。
- 发表偏倚有统计学意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The global rise in antimicrobial resistance (AMR) is a significant health concern. Nitrofurantoin is used as a first-line antibiotic against many uropathogenic bacterial pathogens, including uropathogenic Escherichia coli (UPEC), and an analysis is required to assess the current global prevalence of nitrofurantoin-resistant UPEC. METHODS: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a literature search using PubMed and Google Scholar was performed to find studies reporting nitrofurantoin-resistant UPEC in humans. Studies were included/excluded based on predefined criteria and focused only on isolates collected from the urinary tract. The quality of the studies was assessed using the Joanna Briggs Institute's (JBI's) Checklist for Prevalence Studies. Statistical analysis was performed using Metafor and Meta (R packages) to estimate the pooled prevalence, assess publication bias and perform heterogeneity analysis. RESULTS: Sixty-three studies comprising 774 499 UPEC isolates collected between 1996 and 2024 were analysed and demonstrated a global pooled prevalence of nitrofurantoin-resistant UPEC isolates to be 6.9% (95% CI: 4.8%-9.7%). Continent-wise subgroup analysis showed Europe to have the lowest prevalence, while Asia has the highest prevalence. Decade-wise subgroup analysis showed the global prevalence increased from 2.8% (1996-04) to 8.2% (2005-14) and then decreased to 7.6% in the last decade (2015-24). Substantial heterogeneity was seen among the studies examined, as well as statistically significant publication bias. CONCLUSIONS: The findings show considerable global prevalence of nitrofurantoin-resistant UPEC isolates, with the prevalence being higher in low- and middle-income countries (LMICs). Sufficient education should be provided where possible, and antimicrobial stewardship should be intensified to slow the rate of AMR increase worldwide.
引用
- Larkin C, Valappil SP, Palanisamy N, et al. Global prevalence of nitrofurantoin-resistant uropathogenic Escherichia coli (UPEC) in humans: a systematic review and meta-analysis. J Antimicrob Chemother. 2025. PMID: 40833762. doi:10.1093/jac/dkaf305
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。